Glutamate Receptor Antagonist: A Potential Threat to Developing Nervous System

Glutamate receptor antagonists are powerful drugs that are extensively used in modern medicine for their analgesic and anaesthetic properties

- Sheikh Uzma Farooq, Aditya Sharma

These drugs are primarily used to relieve pain during surgical procedures, manage chronic pain management, and treat neurological disorders like epilepsy and Alzheimer's disease. The research studies have shown that glutamate receptor antagonists might be toxic to the developing nervous system, particularly in neonates and children. However, despite the obvious risks associated with the use of glutamate receptor antagonists in the developing nervous system, these drugs continue to be widely used in clinical practice. This is due in part to the lack of alternative treatments for certain disorders, as well as a lack of awareness of the long-term risks associated with these drugs.

Glutamate is the primary excitatory neurotransmitter in the central nervous system. It plays an essential role in brain development, including the migration, proliferation, and differentiation of neural cells. Excessive glutamate release can lead to excitotoxicity, a process that damages neurons and other cells in the nervous system. Glutamate receptor antagonists, which inhibit the binding of glutamate to its receptors can prevent or reduce this excitotoxicity.

Receptor type:

There are two major types of glutamate receptors: ionotropic and metabotropic. Ionotropic receptors mediate fast synaptic transmission, while metabotropic receptors modulate longer-term signalling events. Glutamate receptor antagonists can target both ionotropic and metabotropic receptors. Ionotropic antagonist drugs are divided into two subtypes: N-methyl-Daspartate (NMDA) receptor antagonists and alpha-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists.

Receptor antagonist: